In a subgroup analysis of a phase Ib/II clinical study evaluating the regimen of surufatinib combined with camrelizumab, albumin-bound paclitaxel, and S-1 as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), the ORR for pancreatic cancer patients with liver metastases who received the combination treatment was significantly higher than that of patients without liver metastases (90.0 vs 20.0%, P = 0.0017). Here, ALB is linked to familial pancreatic carcinoma.